Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia

Drug resistance and relapse are common challenges in acute myeloid leukemia (AML), particularly in an aggressive subset bearing internal tandem duplications (ITDs) of the FLT3 receptor (FLT3-ITD(+)). The tyrosine kinase inhibitor gilteritinib is approved for the treatment of relapse/refractory AML w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavorka Thomas, Megan E., Jeon, Jae Yoon, Talebi, Zahra, Buelow, Daelynn R., Silvaroli, Josie, Campbell, Moray J., Sparreboom, Alex, Pabla, Navjot, Baker, Sharyn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153019/
https://www.ncbi.nlm.nih.gov/pubmed/34614509
http://dx.doi.org/10.1182/bloodadvances.2021005614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153019/
https://www.ncbi.nlm.nih.gov/pubmed/34614509
http://dx.doi.org/10.1182/bloodadvances.2021005614

Ejemplares similares